Sizes of PCR fragments determined by the QiaXcel system.

<p>A–Standard loci. B–Hypervariable loci.</p

Discrepant results for hypervariable loci.

<p>Discrepant results for hypervariable loci.</p

Combined agreement rates between QiaXcel and reference methods.

<p>Combined agreement rates between QiaXcel and reference methods.</p

Discrepant results for standard loci across two centres.

<p>Discrepant results for standard loci across two centres.</p

Interlaboratory agreement rates.

<p>Hypervariable loci shown in red colour. In cases where results from both laboratories were incorrect, these values were not included in discrepancies.</p

External Quality Control modules and specimen panel composition for six rounds, 2010–2014.

<p>External Quality Control modules and specimen panel composition for six rounds, 2010–2014.</p

Smear microscopy error rates for microscopy diagnosis by Ziehl-Neelsen, auramine or Kinyoun methods.

<p>Smear microscopy error rates for microscopy diagnosis by Ziehl-Neelsen, auramine or Kinyoun methods.</p

Laboratories participating in EQA rounds and modules.

<p>Laboratories participating in EQA rounds and modules.</p

Core common clinical and demographic characteristics of patients from the 2002-3 TB Cohort and 2008 XDRTB Cohort^*.

<p>*Note: 3 people do not contribute any survival time data.</p

Uni- and multivariate Cox regression models of predictors of death.

<p>*Three people died on the same date as diagnosis and hence do not contribute any time to the analysis.</p><p>**In the multivariate Cox model age was taken as a continuous variable.</p>∧<p>Patients without available DST results from 2002-3 TB Cohort are excluded from the analysis.</p>#<p>All variables from univariate analysis significant at 10% significance level are included into multivariate analysis (2002-3 TB Cohort); multivariate analysis was not performed for 2008 XDRTB Cohort as no significant variable were identified at univariate analysis in this group.</p>$<p>In 2002-3 Cohort re-treatment cases included relapses only; in 2008 XDRTB Cohort re-treatment cases include relapses, return after default, treatment after failure, chronic patients.</p